Form: 8-K

Current report filing

July 20, 2007

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
___________________
 
FORM 8-K
___________________
 
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
Date of Report: July 16, 2007
(Date of earliest event reported)
 
NOVELOS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
 
333-119366
 
04-3321804
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification Number)
 
 
One Gateway Center, Suite 504
Newton, MA 02458
(Address of principal executive offices)
 
(617) 244-1616
(Registrant's telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
 
On July 16, 2007, the shareholders of Novelos Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase to 150,000,000 the number of shares of common stock, par value $.00001, the Company is authorized to issue (the “Amendment”). The Amendment became effective on July 16, 2007 upon the filing of the Amendment with the Delaware Secretary of State’s office.
 
Item 9.01 Financial Statements and Exhibits
 
(d)
Exhibits
 
 
3.1
Certificate of Amendment to Amended and Restated Certificate of Incorporation dated July 16, 2007.
 
 
 
 
2

 

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
Dated: July 19, 2007 NOVELOS THERAPEUTICS, INC.
 
 
 
 
 
 
  By:   /s/ Harry S. Palmin
 
Name: Harry S. Palmin
  Title: President and Chief Executive Officer

 
    
 
3

 

EXHIBIT INDEX
 
Exhibit No.
 
Description
   
3.1
Certificate of Amendment to Amended and Restated Certificate of Incorporation dated July 16, 2007
   

 

 
 
4